CRP and sarcopenia: Some biomarkers associated with physical frailty and sarcopenia have been identified, such as gut bacteria and markers of inflammation [15], as well as C-reactive protein (CRP) [15,16], also a marker of muscle wasting in cancer cachexia [17], but longitudinal patient studies are yet to be undertaken to evaluate the potential of these biomarkers to predict onset, treatment response and the progression of such muscle wasting disease.